Organon (OGN) Other Non-Current Liabilities (2020 - 2026)
Organon (OGN) recorded quarterly Other Non-Current Liabilities of $984.0 million in Q1 2026, down 2.38% quarter-over-quarter from $1.0 billion in Q4 2025, and down 1.01% on a YoY basis from $994.0 million in Q1 2025.
Organon (OGN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Organon's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $984.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 1.01% year-over-year to $984.0 million; the TTM figure through Mar 2026 stood at $984.0 million (down 1.01% YoY), while the FY2025 annual figure was $1.0 billion, up 3.17% from the prior year.
- Other Non-Current Liabilities was $984.0 million for Q1 2026 at Organon, down from $1.0 billion in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.1 billion in Q3 2025 to a low of $393.0 million in Q2 2023.
- Historically, Other Non-Current Liabilities has averaged $669.3 million across 5 years, with a median of $548.0 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities slumped 75.42% in 2022, then soared 137.14% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $411.0 million in 2022, then rose by 0.24% to $412.0 million in 2023, then jumped by 137.14% to $977.0 million in 2024, then climbed by 3.17% to $1.0 billion in 2025, then fell by 2.38% to $984.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $984.0 million (Q1 2026), $1.0 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 984.00 Mn |
| Dec 31, 2025 | 1.01 Bn |
| Sep 30, 2025 | 1.12 Bn |
| Jun 30, 2025 | 1.12 Bn |
| Mar 31, 2025 | 994.00 Mn |
| Dec 31, 2024 | 977.00 Mn |
| Sep 30, 2024 | 674.00 Mn |
| Jun 30, 2024 | 548.00 Mn |
| Mar 31, 2024 | 549.00 Mn |
| Dec 31, 2023 | 412.00 Mn |
| Sep 30, 2023 | 421.00 Mn |
| Jun 30, 2023 | 393.00 Mn |
| Mar 31, 2023 | 421.00 Mn |
| Dec 31, 2022 | 411.00 Mn |
| Sep 30, 2022 | 441.00 Mn |
| Jun 30, 2022 | 448.00 Mn |
| Mar 31, 2022 | 454.00 Mn |
| Dec 31, 2021 | 463.00 Mn |
| Sep 30, 2021 | 506.00 Mn |
| Jun 30, 2021 | 487.00 Mn |